Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 10 of 14, showing 10 Applications out of 131 total, starting on record 91, ending on 100

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

91.

ECCT/23/03/03   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
 
12-05-2023 View

92.

ECCT/23/01/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Ogutu Bernhards Ragama
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county)
4. Kombewa CRC (Kisumu county)
 
24-05-2023 View

93.

ECCT/23/02/02   KARISMA
    An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric participants with severe Plasmodium falciparum malaria(KARISMA – KAE609’s Role in Severe Malaria)   
Principal Investigator(s)
1. Simon Kariuki
Site(s) in Kenya
KEMRI-CGHR,
 
01-06-2023 View

94.

ECCT/23/02/01   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Videlis Nduba
2. Walter Otieno
3. Isaac Tsikhutsu
Site(s) in Kenya
1. AHERO CLINICAL TRIALS UNIT (Kisumu county)
2. KEMRI-Walter Reed-Kericho (Kericho county)
3. KEMRI: Siaya Clinical Research Annexe (Kisumu county)
4. Kombewa Clinical Research Centre (Kisumu county)
 
14-06-2023 View

95.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
19-06-2023 View

96.

ECCT/23/03/07   PLATINUM STUDY
    (PLATINUM): A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Godfrey (Site 5001) Allan Otieno
2. Bernhard Ragama Ogutu
3. John (Site 5002) Orimbo
Site(s) in Kenya
1. KEMRI Kondele Children Hospital (Kisumu county)
2. AHERO CLINICAL TRIALS UNIT (Kisumu county)
 
21-07-2023 View

97.

ECCT/23/03/01   Micronutrient supplementation
    Optimizing nutrient supplementation among pregnant and reproductive age women in Kenya (Virutubisho)   
Principal Investigator(s)
1. DR. Martha Kaeni Mwangome
Site(s) in Kenya
KILIFI
 
24-07-2023 View

98.

ECCT/23/07/04   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Dr. Janet Oyieko
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county)
 
28-08-2023 View

99.

ECCT/23/07/05   Sabin
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults    
Principal Investigator(s)
1. Prof. Videlis Nduba Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
11-09-2023 View

100.

ECCT/23/06/08   TSCV3000
    Age-descending, randomized, placebo-controlled Phase 2 trial in three sites in sub-Saharan Africa to assess the safety and immunogenicity of a parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) versus placebo   
Principal Investigator(s)
1. RICHARD ONYANDO OMORE
Site(s) in Kenya
1. SIAYA COUNTY REFERRAL HOSPITAL (Siaya county)
2. ST. ELIZABETH LWAK HOSPITAL (Siaya county)
 
25-09-2023 View